M Verstraete

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Thrombosis, Ischemic Stroke, Cardiovascular Disease +9

RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION

M Verstraete, M Bory, D Collen et al. · The Lancet · 1985 · 752 citations

Thrombosis, Cardiovascular Disease, Fibrinolysis +10

Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.

M Verstraete, Graham Miller, Henri Bounameaux et al. · Circulation · 1988 · 406 citations

Thrombosis, Pulmonary Embolism, Mg Rt-pa +13

Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis. EFFECT OF MOLECULAR FORM AND DOSE OF ACTIVATOR, AGE OF THE THROMBUS, AND ROUTE OF ADMINISTRATION

D Collen, Jean Marie Stassen, M Verstraete · Journal of Clinical Investigation · 1983 · 243 citations · Full text

Percent Thrombolysis, Biomedical Engineering, Human Extrinsic +18

DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION

M Verstraete, Ronald W. Brower, D Collen et al. · The Lancet · 1985 · 240 citations

Thrombosis, Cardiovascular Disease, Atherosclerosis +12